Prostate cancer surface targets for car T cell therapy or metastatic prostate cancer in the car T cell era: My kingdom for the target!

Sergey V. Kulemzin, Andrey A. Gorchakov, Aleksandr V. Taranin

Research output: Contribution to journalReview articlepeer-review

Abstract

Despite the progress achieved in target, chemo-, and radiotherapy, treatment options for patients with latestage metastatic castration-resistant prostate cancer are presently very limited. Use of dendritic cell-based vaccines exemplified by sipuleucel-T appears is rarely curative and is effective in only a fraction of such patients. Given the success of CAR T cell therapy in the field of B cell malignancies, significant efforts have been made to adapt this powerful technology to the problem of metastatic prostate cancer. Availability of unique prostate cancer surface targets for CAR T cells has thereby become a pressing issue in the field of CAR design. Ideally, such targets should be absent from normal cells or tissues, be present on all prostate cancer cells across all patients, and be indispensable for the survival of cancer cells. In reality, however, none of the prostate cancer-associated surface markers described to date are matching such description. Here, we catalogue the list of tested as well as prospective surface antigens to be used as targets for CAR T cell therapy, and discuss the aspects of their safety and potential efficacy.

Original languageEnglish
Pages (from-to)19-28
Number of pages10
JournalCellular Therapy and Transplantation
Volume8
Issue number4
DOIs
Publication statusPublished - 1 Nov 2019

Keywords

  • CAR T cells
  • Chimeric antigen receptor
  • Immunotherapy
  • Metastatic prostate cancer

Fingerprint

Dive into the research topics of 'Prostate cancer surface targets for car T cell therapy or metastatic prostate cancer in the car T cell era: My kingdom for the target!'. Together they form a unique fingerprint.

Cite this